🔍 However, challenges arise with complex molecules like monoclonal antibodies and detecting certain modifications.
🔄 Mixing techniques, like using HPLC with MS, can enhance analysis accuracy, addressing regulatory hurdles too. Careful method selection is crucial for optimal results.
Introduction:
The article discusses the increasing significance of liquid chromatography-mass spectrometry (LC-MS) in biopharmaceutical analysis, while also addressing the complexities and challenges associated with selecting the appropriate LC-MS techniques for various production processes.
- LC-MS is recognized as a gold standard for analyzing biopharmaceuticals, combining chromatography and mass spectrometry to provide detailed biochemical information.
- The complexity of modern biopharmaceuticals, particularly large macromolecules, poses challenges for effective analysis using conventional LC-MS techniques.
- Challenges include difficulties in analyzing intact proteins, insufficient sequencing coverage of monoclonal antibodies, and issues with detecting post-translational modifications (PTMs).
- Regulatory compliance adds another layer of complexity, as stringent validation of LC-MS techniques is required, especially for novel compounds.
- A “mix and match” approach, where various LC-MS techniques are combined with other analytical methods, is proposed to effectively address these challenges, particularly in the context of analyzing PTMs.
Conclusion:
The article concludes that while LC-MS remains a crucial technology in biopharmaceutical analysis, flexibility in technique selection and the integration of additional analytical methods are essential to overcoming existing challenges. The proposed approaches aim to enhance the accuracy and efficacy of biopharmaceutical substance analysis, addressing regulatory demands and the complexities of modern macromolecular structures.
